Endonovo Therapeutics, Inc.
ENDV
$0.0003
$0.0002200.00%
Recommendation
--
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -137.13% | -71.46% | 155.91% | -2,043.21% | 76.11% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -124.07% | 176.92% | -80.69% | -35.46% | 9.82% |
| Total Other Non-Cash Items | 108.53% | 63.84% | -165.74% | 4,743.21% | -117.60% |
| Change in Net Operating Assets | -41.22% | 9.71% | 43.53% | -42.17% | -13.58% |
| Cash from Operations | 60.55% | 4.27% | 23.19% | -82.00% | 40.00% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -66.44% | -- | -- | -56.67% | 0.00% |
| Total Debt Repaid | -344.44% | 80.43% | -411.11% | -50.00% | 14.29% |
| Issuance of Common Stock | -91.74% | -77.78% | 45.77% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -82.51% | 1.90% | -9.14% | 37.76% | 0.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -250.23% | 100.93% | 146.96% | -199.57% | 138.50% |
